TY - JOUR A1 - Muthukumar, Yazh A1 - Münkemer, Johanna A1 - Mathieu, Daniel A1 - Richter, Christian A1 - Schwalbe, Harald A1 - Steinmetz, Heinrich A1 - Kessler, Wolfgang A1 - Reichelt, Joachim A1 - Beutling, Ulrike A1 - Frank, Ronald A1 - Büssow, Konrad A1 - Heuvel, Joop van den A1 - Brönstrup, Mark A1 - Taylor, Richard E. A1 - Laschat, Sabine A1 - Sasse, Florenz T1 - Investigations on the mode of action of gephyronic acid, an inhibitor of eukaryotic protein translation from myxobacteria T2 - PLoS one N2 - The identification of inhibitors of eukaryotic protein biosynthesis, which are targeting single translation factors, is highly demanded. Here we report on a small molecule inhibitor, gephyronic acid, isolated from the myxobacterium Archangium gephyra that inhibits growth of transformed mammalian cell lines in the nM range. In direct comparison, primary human fibroblasts were shown to be less sensitive to toxic effects of gephyronic acid than cancer-derived cells. Gephyronic acid is targeting the protein translation system. Experiments with IRES dual luciferase reporter assays identified it as an inhibitor of the translation initiation. DARTs approaches, co-localization studies and pull-down assays indicate that the binding partner could be the eukaryotic initiation factor 2 subunit alpha (eIF2α). Gephyronic acid seems to have a different mode of action than the structurally related polyketides tedanolide, myriaporone, and pederin and is a valuable tool for investigating the eukaryotic translation system. Because cancer derived cells were found to be especially sensitive, gephyronic acid could potentially find use as a drug candidate. KW - Protein translation KW - Internal ribosome entry site KW - Luciferase KW - Esters KW - Eukaryota KW - Translation initiation KW - Biotin KW - Phosphorylation Y1 - 2018 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/46886 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-468867 SN - 1932-6203 N1 - This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. VL - 13 IS - (7): e0201605 SP - 1 EP - 14 PB - PLoS CY - Lawrence, Kan. ER -